Biocept Launches Diagnostic Assay for BRAF Mutations in Patients with Melanoma
New test provides physicians with a liquid biopsy option to reach informed treatment decisions for patients with melanoma and other tumors
About half of all patients with melanoma have changes (mutations) in the
BRAF gene. These changes cause the gene to make an altered BRAF protein
that signals the melanoma cells to grow and divide quickly. Drugs such
as Vemaurafenib (Zelboraf™) from
In addition to its new biomarker test for melanoma,
"Analysis of BRAF mutations from a blood sample allows rapid diagnosis
of the BRAF V600E and V600K status in patients with advanced melanoma
and could enable therapy improvement for patients who were previously
found to be negative through tissue biopsy due to tumor heterogeneity,"
said
"Due to their high sensitivity, our mutation tests offer a great
advantage in assessing patients with advanced disease and provide a new
tool for following patients who are likely to be at high risk for
disease recurrence," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to the potential of our
diagnostic assays to help physicians identify patients who might benefit
from currently available targeted therapies, our impact on diagnostic
strategies and planned future offerings, such statements are
forward-looking, and are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The reader is
cautioned not to put undue reliance on these forward-looking statements,
as these statements are subject to numerous risk factors as set forth in
our
View source version on businesswire.com: http://www.businesswire.com/news/home/20150714005496/en/
Investor Contact:
LHA
jcain@lhai.com
310-691-7100
Source:
News Provided by Acquire Media